Cendakimab (Anti-IL-13) | Interleukins antibody | Read Reviews & Product Use Citations

Cendakimab (anti-IL-13) is a humanized, recombinant monoclonal antibody against the interleukin-13 (IL-13) molecule with the potential to treat allergic/inflammatory diseases (e.g., asthma and eosinophilic esophagitis). MW: 146.44 KD.

Purity & Quality Control

Batch: A294901 Purity: 99% Protein concentration: 7.9mg/ml Endotoxin Level: ＜1EU/mg

99

Choose Selective Interleukins Inhibitors

Biological Activity

Description	Cendakimab (anti-IL-13) is a humanized, recombinant monoclonal antibody against the interleukin-13 (IL-13) molecule with the potential to treat allergic/inflammatory diseases (e.g., asthma and eosinophilic esophagitis). MW: 146.44 KD.

References
[1] Tripp CS, et al. Adv Ther. 2017;34(6):1364-1381.

References

[1] Tripp CS, et al. Adv Ther. 2017;34(6):1364-1381.

Product Details

CAS No.	2151032-62-9
Molecular Weight	146.44
Isotype	Human IgG1
Source	CHO
Purification	AKTA
Sterility	0.2 μM filtered
Formulation	100mMPro-Ac,20mMArg-Ac，pH5.0
Storage (From the date of receipt)	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field